ArticleFrontiers in endocrinology2025
Comparison of
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association Between Biochemical Parameters, Parathyroid Gland Morphometry, and Dual-Phase MIBI SPECT/CT Findings in Primary Hyperparathyroidism.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Accurate localization of hyperactive parathyroid glands is essential in managing primary hyperparathyroidism. Despite advances in imaging, discordant findings still complicate surgical planning. Tc-99m-sestaMIBI SPECT/CT (MIBI SPECT/CT) and Objective: This study compared the findings of FCH PET/CT and MIBI SPECT/CT with intraoperative outcomes in patients who underwent parathyroidectomy for primary hyperparathyroidism. In discordant cases, the relative diagnostic performance and postoperative outcomes of the two modalities were analyzed. Materials and methods: We retrospectively reviewed 133 patients who underwent parathyroidectomy between January 2020 and December 2024 and had both MIBI SPECT/CT and FCH PET/CT. Patients were classified according to concordance between imaging and surgical localization: Group 1 (both modalities concordant), Group 2 (MIBI concordant only), Group 3 (FCH concordant only), and Group 4 (both discordant). Diagnostic performance (sensitivity and PPV) and biochemical cure-defined as normalization of parathyroid hormone (PTH) and calcium at 6 and 12 months-were compared between Groups 2 and 3. Results: Of 133 patients, 82 (61.7%) were in Group 1, 5 (3.8%) in Group 2, 37 (27.8%) in Group 3, and 9 (6.8%) in Group 4. Sensitivity and PPV were 74.4% and 86.1% for MIBI, and 97.5% and 91.5% for FCH PET/CT, respectively. The biochemical cure rate was 80.0% vs 94.6% at 6 months and 50.0% vs 87.5% at 12 months for Groups 2 and 3, with calcium levels remaining within the normal range. Preoperative PTH levels and chief-cell proportions were higher in Group 3 (91.9%) than in Group 1 (82.6%). Discussion: FCH PET/CT demonstrated better diagnostic performance and higher cure rates than MIBI SPECT/CT in discordant cases. Although differences were not statistically significant, they may be influenced by preoperative parathyroid activity and histologic composition. Conclusion: FCH PET/CT showed a trend toward improved diagnostic performance and postoperative cure compared with MIBI SPECT/CT in discordant cases. While not superior in all situations, it can complement MIBI SPECT/CT and enhance surgical decision-making in complex clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.